drugset / Trial / NCT00941109
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how the body absorbs decitabine when taken orally in patients with Myelodysplastic Syndrome (MDS). Safety will also be assessed for this oral dose.
Timeline
- Start
- 2009-12
- Primary completion
- 2011-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 20 mg/m2 | Oral |
| Subject | Decitabine | Small molecule | 30 mg | Oral |
| Subject | Decitabine | Small molecule | 60 mg | Oral |
| Subject | Decitabine | Small molecule | 120 mg | Oral |
| Subject | Decitabine | Small molecule | 240 mg | Oral |